APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Varicella Vaccine

Varicella vaccine, also known as chickenpox vaccine, is a vaccine that protects against chickenpox. One dose of vaccine prevents 95% of moderate disease and 100% of severe disease. Two doses of vaccine is more effective than one. If given to those who are not immune within five days of exposure to chickenpox it prevents most cases of disease. Vaccinating a large portion of the population also protects those who are not vaccinated. It is given by injection just under the skin

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Varicella vaccine, also known as chickenpox vaccine, is a vaccine that protects against chickenpox. One dose of vaccine prevents 95% of moderate disease and 100% of severe disease. Two doses of vaccine is more effective than one. If given to those who are not immune within five days of exposure to chickenpox it prevents most cases of disease. Vaccinating a large portion of the population also protects those who are not vaccinated. It is given by injection just under the skin

Selected research

Market Outlook & Growth Opportunities

Global Varicella Vaccine Market Outlook and Growth Opportunities 2026

Report ID 174045190423 December 2025195 pages

Choose your research edition.

Industry ResearchVaricella Vaccine Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Varicella Vaccine Industry Growth and Trends Forecast to 203299 pages · $3,450 USDMarket StructureGlobal Varicella Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Varicella Vaccine Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Varicella Vaccine Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

Varicella vaccine, also known as chickenpox vaccine, is a vaccine that protects against chickenpox. One dose of vaccine prevents 95% of moderate disease and 100% of severe disease. Two doses of vaccine is more effective than one. If given to those who are not immune within five days of exposure to chickenpox it prevents most cases of disease. Vaccinating a large portion of the population also protects those who are not vaccinated. It is given by injection just under the skin

Global Varicella Vaccine key players include Merck, Shanghai Institute, Changsheng, Keygen, GSK, etc.

Asia is the largest market, with a share over 35%, followed by US and Europe, both have a share over 55%.

Read the full market overview

In terms of product, Freeze-Dried Powder is the largest segment, with a share over 50%. And in terms of application, the largest application is Kids Injection, followed by Adults Injection, etc.

This report provides an overview of the global Varicella Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Varicella Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Varicella Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Varicella Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Varicella Vaccine Segment by Company

Merck

GSK

Shanghai Institute

BCHT

Changsheng

Keygen

Green Cross

Biken

Varicella Vaccine Segment by Type

Injection

Freeze-Dried Powder

Varicella Vaccine Segment by Application

Kids Injection

Adults Injection

Varicella Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Varicella Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Varicella Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Varicella Vaccine significant trends, drivers, influence factors in global and regions.

6. To analyze Varicella Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Varicella Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Varicella Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Varicella Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Varicella Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Varicella Vaccine industry.

Chapter 3: Detailed analysis of Varicella Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Varicella Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Varicella Vaccine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Varicella Vaccine Industry Trends Table 2. Varicella Vaccine Industry Drivers Table 3. Varicella Vaccine Industry Opportunities and Challenges Table 4. Varicella Vaccine Industry Restraints Table 5. Global Varicella Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Varicella Vaccine Revenue Share by Company (2021-2026) Table 7. Global Varicella Vaccine Sales Volume by Company (M Doses) & (2021-2026) Table 8. Global Varicella Vaccine Sales Volume Share by Company (2021-2026) Table 9. Global Varicella Vaccine Average Price (USD/Dose) of Company (2021-2026) Table 10. Global Varicella Vaccine Company Ranking, (2024-2026) & (USD Million) Table 11. Global Varicella Vaccine Key Company Manufacturing Base & Headquarters Table 12. Global Varicella Vaccine Company, Product Type & Application Table 13. Global Varicella Vaccine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Varicella Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Injection Table 18. Significant Companies of Freeze-Dried Powder Table 19. Global Varicella Vaccine Sales Volume by Type 2021 VS 2025 VS 2032 (M Doses) Table 20. Global Varicella Vaccine Sales Volume by Type (2021-2026) & (M Doses) Table 21. Global Varicella Vaccine Sales Volume by Type (2027-2032) & (M Doses) Table 22. Global Varicella Vaccine Sales Volume Share by Type (2021-2026) Table 23. Global Varicella Vaccine Sales Volume Share by Type (2027-2032) Table 24. Global Varicella Vaccine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Varicella Vaccine Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Varicella Vaccine Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Varicella Vaccine Sales Value Share by Type (2021-2026) Table 28. Global Varicella Vaccine Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Kids Injection Table 30. Significant Companies of Adults Injection Table 31. Global Varicella Vaccine Sales Volume by Application 2021 VS 2025 VS 2032 (M Doses) Table 32. Global Varicella Vaccine Sales Volume by Application (2021-2026) & (M Doses) Table 33. Global Varicella Vaccine Sales Volume by Application (2027-2032) & (M Doses) Table 34. Global Varicella Vaccine Sales Volume Share by Application (2021-2026) Table 35. Global Varicella Vaccine Sales Volume Share by Application (2027-2032) Table 36. Global Varicella Vaccine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Varicella Vaccine Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Varicella Vaccine Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Varicella Vaccine Sales Value Share by Application (2021-2026) Table 40. Global Varicella Vaccine Sales Value Share by Application (2027-2032) Table 41. Global Varicella Vaccine Sales by Region: 2021 VS 2025 VS 2032 (M Doses) Table 42. Global Varicella Vaccine Sales by Region (2021-2026) & (M Doses) Table 43. Global Varicella Vaccine Sales Market Share by Region (2021-2026) Table 44. Global Varicella Vaccine Sales by Region (2027-2032) & (M Doses) Table 45. Global Varicella Vaccine Sales Market Share by Region (2027-2032) Table 46. Global Varicella Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Varicella Vaccine Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Varicella Vaccine Sales Value Share by Region (2021-2026) Table 49. Global Varicella Vaccine Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Varicella Vaccine Sales Value Share by Region (2027-2032) Table 51. Global Varicella Vaccine Market Average Price (USD/Dose) by Region (2021-2026) Table 52. Global Varicella Vaccine Market Average Price (USD/Dose) by Region (2027-2032) Table 53. Global Varicella Vaccine Sales by Country: 2021 VS 2025 VS 2032 (M Doses) Table 54. Global Varicella Vaccine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Varicella Vaccine Sales by Country (2021-2026) & (M Doses) Table 56. Global Varicella Vaccine Sales Market Share by Country (2021-2026) Table 57. Global Varicella Vaccine Sales by Country (2027-2032) & (M Doses) Table 58. Global Varicella Vaccine Sales Market Share by Country (2027-2032) Table 59. Global Varicella Vaccine Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Varicella Vaccine Sales Value Market Share by Country (2021-2026) Table 61. Global Varicella Vaccine Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Varicella Vaccine Sales Value Market Share by Country (2027-2032) Table 63. Merck Company Information Table 64. Merck Business Overview Table 65. Merck Varicella Vaccine Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 66. Merck Varicella Vaccine Product Portfolio Table 67. Merck Recent Development Table 68. GSK Company Information Table 69. GSK Business Overview Table 70. GSK Varicella Vaccine Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 71. GSK Varicella Vaccine Product Portfolio Table 72. GSK Recent Development Table 73. Shanghai Institute Company Information Table 74. Shanghai Institute Business Overview Table 75. Shanghai Institute Varicella Vaccine Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 76. Shanghai Institute Varicella Vaccine Product Portfolio Table 77. Shanghai Institute Recent Development Table 78. BCHT Company Information Table 79. BCHT Business Overview Table 80. BCHT Varicella Vaccine Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 81. BCHT Varicella Vaccine Product Portfolio Table 82. BCHT Recent Development Table 83. Changsheng Company Information Table 84. Changsheng Business Overview Table 85. Changsheng Varicella Vaccine Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 86. Changsheng Varicella Vaccine Product Portfolio Table 87. Changsheng Recent Development Table 88. Keygen Company Information Table 89. Keygen Business Overview Table 90. Keygen Varicella Vaccine Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 91. Keygen Varicella Vaccine Product Portfolio Table 92. Keygen Recent Development Table 93. Green Cross Company Information Table 94. Green Cross Business Overview Table 95. Green Cross Varicella Vaccine Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 96. Green Cross Varicella Vaccine Product Portfolio Table 97. Green Cross Recent Development Table 98. Biken Company Information Table 99. Biken Business Overview Table 100. Biken Varicella Vaccine Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 101. Biken Varicella Vaccine Product Portfolio Table 102. Biken Recent Development Table 103. Key Raw Materials Table 104. Raw Materials Key Suppliers Table 105. Varicella Vaccine Distributors List Table 106. Varicella Vaccine Customers List Table 107. Research Programs/Design for This Report Table 108. Authors List of This Report Table 109. Secondary Sources Table 110. Primary Sources List of Figures Figure 1. Varicella Vaccine Product Image Figure 2. Global Varicella Vaccine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Varicella Vaccine Sales Value (2021-2032) & (US$ Million) Figure 4. Global Varicella Vaccine Sales (2021-2032) & (M Doses) Figure 5. Global Varicella Vaccine Sales Average Price (USD/Dose) & (2021-2032) Figure 6. Global Varicella Vaccine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Injection Image Figure 10. Freeze-Dried Powder Image Figure 11. Global Varicella Vaccine Sales Volume by Type (2021 VS 2025 VS 2032) & (M Doses) Figure 12. Global Varicella Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Varicella Vaccine Sales Volume Share by Type (2021-2032) Figure 14. Global Varicella Vaccine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Varicella Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Varicella Vaccine Sales Value Share by Type (2021-2032) Figure 17. Kids Injection Image Figure 18. Adults Injection Image Figure 19. Global Varicella Vaccine Sales Volume by Application (2021 VS 2025 VS 2032) & (M Doses) Figure 20. Global Varicella Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Varicella Vaccine Sales Volume Share by Application (2021-2032) Figure 22. Global Varicella Vaccine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Varicella Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Varicella Vaccine Sales Value Share by Application (2021-2032) Figure 25. Global Varicella Vaccine Sales by Region: 2021 VS 2025 VS 2032 (M Doses) Figure 26. Global Varicella Vaccine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Varicella Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Varicella Vaccine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Varicella Vaccine Sales Value (2021-2032) & (US$ Million) Figure 30. North America Varicella Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Varicella Vaccine Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Varicella Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Varicella Vaccine Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Varicella Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Varicella Vaccine Sales Value (2021-2032) & (US$ Million) Figure 36. South America Varicella Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Varicella Vaccine Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Varicella Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Varicella Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Varicella Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Varicella Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Varicella Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Varicella Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Varicella Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Varicella Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Varicella Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Varicella Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Varicella Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Varicella Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Varicella Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Varicella Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Varicella Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Varicella Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Varicella Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Varicella Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Varicella Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Varicella Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Varicella Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Varicella Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Varicella Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Varicella Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Varicella Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Varicella Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Varicella Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Varicella Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Varicella Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Varicella Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Varicella Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Varicella Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Varicella Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Varicella Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Varicella Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Varicella Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Varicella Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Varicella Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Varicella Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Varicella Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Varicella Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Varicella Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Varicella Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Varicella Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Varicella Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Varicella Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Varicella Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Varicella Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Varicella Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Varicella Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Varicella Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Varicella Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Varicella Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Varicella Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Varicella Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Varicella Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Varicella Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Varicella Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Varicella Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Varicella Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Varicella Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Varicella Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Varicella Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Varicella Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Varicella Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Varicella Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Varicella Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Varicella Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Varicella Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Varicella Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Varicella Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Varicella Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Varicella Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Varicella Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Varicella Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Varicella Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Varicella Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Varicella Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Varicella Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Varicella Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Varicella Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Varicella Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Varicella Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Varicella Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Varicella Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Varicella Vaccine Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Varicella Vaccine Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • Injection
  • Freeze-Dried Powder
Applications
  • Kids Injection
  • Adults Injection
Companies covered
  • Merck
  • GSK
  • Shanghai Institute
  • BCHT
  • Changsheng
  • Keygen
  • Green Cross
  • Biken

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Varicella Vaccine Sales Value (2021-2032)
  4. 1.2.2 Global Varicella Vaccine Sales Volume (2021-2032)
  5. 1.2.3 Global Varicella Vaccine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Varicella Vaccine Market Dynamics
  1. 2.1 Varicella Vaccine Industry Trends
  2. 2.2 Varicella Vaccine Industry Drivers
  3. 2.3 Varicella Vaccine Industry Opportunities and Challenges
  4. 2.4 Varicella Vaccine Industry Restraints
3 Varicella Vaccine Market by Company
  1. 3.1 Global Varicella Vaccine Company Revenue Ranking in 2025
  2. 3.2 Global Varicella Vaccine Revenue by Company (2021-2026)
  3. 3.3 Global Varicella Vaccine Sales Volume by Company (2021-2026)
  4. 3.4 Global Varicella Vaccine Average Price by Company (2021-2026)
  5. 3.5 Global Varicella Vaccine Company Ranking (2024-2026)
  6. 3.6 Global Varicella Vaccine Company Manufacturing Base and Headquarters
  7. 3.7 Global Varicella Vaccine Company Product Type and Application
  8. 3.8 Global Varicella Vaccine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Varicella Vaccine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Varicella Vaccine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Varicella Vaccine Market by Type
  1. 4.1 Varicella Vaccine Type Introduction
  2. 4.1.1 Injection
  3. 4.1.2 Freeze-Dried Powder
  4. 4.2 Global Varicella Vaccine Sales Volume by Type
  5. 4.2.1 Global Varicella Vaccine Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Varicella Vaccine Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Varicella Vaccine Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Varicella Vaccine Sales Value by Type
  9. 4.3.1 Global Varicella Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Varicella Vaccine Sales Value by Type (2021-2032)
  11. 4.3.3 Global Varicella Vaccine Sales Value Share by Type (2021-2032)
5 Varicella Vaccine Market by Application
  1. 5.1 Varicella Vaccine Application Introduction
  2. 5.1.1 Kids Injection
  3. 5.1.2 Adults Injection
  4. 5.2 Global Varicella Vaccine Sales Volume by Application
  5. 5.2.1 Global Varicella Vaccine Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Varicella Vaccine Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Varicella Vaccine Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Varicella Vaccine Sales Value by Application
  9. 5.3.1 Global Varicella Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Varicella Vaccine Sales Value by Application (2021-2032)
  11. 5.3.3 Global Varicella Vaccine Sales Value Share by Application (2021-2032)
6 Varicella Vaccine Regional Sales and Value Analysis
  1. 6.1 Global Varicella Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Varicella Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Varicella Vaccine Sales by Region: 2021-2026
  4. 6.2.2 Global Varicella Vaccine Sales by Region (2027-2032)
  5. 6.3 Global Varicella Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Varicella Vaccine Sales Value by Region (2021-2032)
  7. 6.4.1 Global Varicella Vaccine Sales Value by Region: 2021-2026
  8. 6.4.2 Global Varicella Vaccine Sales Value by Region (2027-2032)
  9. 6.5 Global Varicella Vaccine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Varicella Vaccine Sales Value (2021-2032)
  12. 6.6.2 North America Varicella Vaccine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Varicella Vaccine Sales Value (2021-2032)
  15. 6.7.2 Europe Varicella Vaccine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Varicella Vaccine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Varicella Vaccine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Varicella Vaccine Sales Value (2021-2032)
  21. 6.9.2 South America Varicella Vaccine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Varicella Vaccine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Varicella Vaccine Sales Value Share by Country, 2025 VS 2032
7 Varicella Vaccine Country-level Sales and Value Analysis
  1. 7.1 Global Varicella Vaccine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Varicella Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Varicella Vaccine Sales by Country (2021-2032)
  4. 7.3.1 Global Varicella Vaccine Sales by Country (2021-2026)
  5. 7.3.2 Global Varicella Vaccine Sales by Country (2027-2032)
  6. 7.4 Global Varicella Vaccine Sales Value by Country (2021-2032)
  7. 7.4.1 Global Varicella Vaccine Sales Value by Country (2021-2026)
  8. 7.4.2 Global Varicella Vaccine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Varicella Vaccine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Varicella Vaccine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Varicella Vaccine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Varicella Vaccine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Varicella Vaccine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Varicella Vaccine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Varicella Vaccine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Varicella Vaccine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Varicella Vaccine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Varicella Vaccine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Varicella Vaccine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Varicella Vaccine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Varicella Vaccine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Varicella Vaccine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Varicella Vaccine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Varicella Vaccine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Varicella Vaccine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Varicella Vaccine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Varicella Vaccine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Varicella Vaccine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Varicella Vaccine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Varicella Vaccine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Varicella Vaccine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Varicella Vaccine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Varicella Vaccine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Varicella Vaccine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Varicella Vaccine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Varicella Vaccine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Varicella Vaccine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Varicella Vaccine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Varicella Vaccine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Varicella Vaccine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Varicella Vaccine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Varicella Vaccine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Varicella Vaccine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Varicella Vaccine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Varicella Vaccine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Varicella Vaccine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Varicella Vaccine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Varicella Vaccine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Varicella Vaccine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Varicella Vaccine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Varicella Vaccine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Varicella Vaccine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Varicella Vaccine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Varicella Vaccine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Varicella Vaccine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Varicella Vaccine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Varicella Vaccine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Varicella Vaccine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Varicella Vaccine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Varicella Vaccine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Varicella Vaccine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Varicella Vaccine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Varicella Vaccine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Varicella Vaccine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Varicella Vaccine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Varicella Vaccine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Varicella Vaccine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Varicella Vaccine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Varicella Vaccine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Varicella Vaccine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Varicella Vaccine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Varicella Vaccine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Varicella Vaccine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Varicella Vaccine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Varicella Vaccine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Varicella Vaccine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Varicella Vaccine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Varicella Vaccine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Varicella Vaccine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Varicella Vaccine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Varicella Vaccine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Varicella Vaccine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Varicella Vaccine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Varicella Vaccine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Varicella Vaccine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Varicella Vaccine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Varicella Vaccine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Varicella Vaccine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Varicella Vaccine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Varicella Vaccine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Varicella Vaccine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Varicella Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Merck
  2. 8.1.1 Merck Company Information
  3. 8.1.2 Merck Business Overview
  4. 8.1.3 Merck Varicella Vaccine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Merck Varicella Vaccine Product Portfolio
  6. 8.1.5 Merck Recent Developments
  7. 8.2 GSK
  8. 8.2.1 GSK Company Information
  9. 8.2.2 GSK Business Overview
  10. 8.2.3 GSK Varicella Vaccine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 GSK Varicella Vaccine Product Portfolio
  12. 8.2.5 GSK Recent Developments
  13. 8.3 Shanghai Institute
  14. 8.3.1 Shanghai Institute Company Information
  15. 8.3.2 Shanghai Institute Business Overview
  16. 8.3.3 Shanghai Institute Varicella Vaccine Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Shanghai Institute Varicella Vaccine Product Portfolio
  18. 8.3.5 Shanghai Institute Recent Developments
  19. 8.4 BCHT
  20. 8.4.1 BCHT Company Information
  21. 8.4.2 BCHT Business Overview
  22. 8.4.3 BCHT Varicella Vaccine Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 BCHT Varicella Vaccine Product Portfolio
  24. 8.4.5 BCHT Recent Developments
  25. 8.5 Changsheng
  26. 8.5.1 Changsheng Company Information
  27. 8.5.2 Changsheng Business Overview
  28. 8.5.3 Changsheng Varicella Vaccine Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Changsheng Varicella Vaccine Product Portfolio
  30. 8.5.5 Changsheng Recent Developments
  31. 8.6 Keygen
  32. 8.6.1 Keygen Company Information
  33. 8.6.2 Keygen Business Overview
  34. 8.6.3 Keygen Varicella Vaccine Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Keygen Varicella Vaccine Product Portfolio
  36. 8.6.5 Keygen Recent Developments
  37. 8.7 Green Cross
  38. 8.7.1 Green Cross Company Information
  39. 8.7.2 Green Cross Business Overview
  40. 8.7.3 Green Cross Varicella Vaccine Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Green Cross Varicella Vaccine Product Portfolio
  42. 8.7.5 Green Cross Recent Developments
  43. 8.8 Biken
  44. 8.8.1 Biken Company Information
  45. 8.8.2 Biken Business Overview
  46. 8.8.3 Biken Varicella Vaccine Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Biken Varicella Vaccine Product Portfolio
  48. 8.8.5 Biken Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Varicella Vaccine Value Chain Analysis
  2. 9.1.1 Varicella Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Varicella Vaccine Sales Mode & Process
  6. 9.2 Varicella Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Varicella Vaccine Distributors
  9. 9.2.3 Varicella Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst